The risks of adverse events with venlafaxine and mirtazapine versus ‘active placebo’, placebo, or no intervention for adults with major depressive disorder: a protocol for two separate systematic reviews with meta-analysis and Trial Sequential Analysis

MLA

Caroline Kamp Jørgensen, et al. “The Risks of Adverse Events with Venlafaxine and Mirtazapine versus ‘Active Placebo’, Placebo, or No Intervention for Adults with Major Depressive Disorder: A Protocol for Two Separate Systematic Reviews with Meta-Analysis and Trial Sequential Analysis.” Systematic Reviews, vol. 12, no. 1, Mar. 2023, pp. 1–10. EBSCOhost, https://doi.org/10.1186/s13643-023-02221-5.

APA

Caroline Kamp Jørgensen, Sophie Juul, Faiza Siddiqui, Mark Abie Horowitz, Joanna Moncrieff, Klaus Munkholm, Michael Pascal Hengartner, Irving Kirsch, Christian Gluud, & Janus Christian Jakobsen. (2023). The risks of adverse events with venlafaxine and mirtazapine versus ‘active placebo’, placebo, or no intervention for adults with major depressive disorder: a protocol for two separate systematic reviews with meta-analysis and Trial Sequential Analysis. Systematic Reviews, 12(1), 1–10. https://doi.org/10.1186/s13643-023-02221-5

Chicago

Caroline Kamp Jørgensen, Sophie Juul, Faiza Siddiqui, Mark Abie Horowitz, Joanna Moncrieff, Klaus Munkholm, Michael Pascal Hengartner, Irving Kirsch, Christian Gluud, and Janus Christian Jakobsen. 2023. “The Risks of Adverse Events with Venlafaxine and Mirtazapine versus ‘Active Placebo’, Placebo, or No Intervention for Adults with Major Depressive Disorder: A Protocol for Two Separate Systematic Reviews with Meta-Analysis and Trial Sequential Analysis.” Systematic Reviews 12 (1): 1–10. doi:10.1186/s13643-023-02221-5.